Rodman Rogers, MD
Urology · San Francisco, CANPI 1073617023
Payments from drug & device makers
Across 428 payments — averaging $27.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$2K
- Astellas Pharma US Inc$2K
- AbbVie$1K
- Johnson & Johnson$917
- Urovant Sciences Inc$780
- Boston Scientific$771
- plus $4K from 33 others
What the payments were for
- Food & beverage$11,46399%
- Education$1051%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 82 | $2,470 |
| Astellas Pharma US Inc | 76 | $1,783 |
| AbbVie(2 entities) | 41 | $1,033 |
| Johnson & Johnson | 30 | $917 |
| Urovant Sciences Inc | 27 | $780 |
| Boston Scientific | 35 | $771 |
| Procept Biorobotics Corporation | 7 | $418 |
| Blue Earth Diagnostics | 14 | $371 |
| Pfizer | 15 | $310 |
| Ferring Pharmaceuticals Inc. | 16 | $279 |
| Antares Pharma, Inc. | 10 | $216 |
| Neotract Inc. | 4 | $215 |
| Dornier Medtech America, Inc | 1 | $205 |
| Dendreon Pharmaceuticals LLC | 10 | $166 |
| Rochester Medical Corporation | 4 | $122 |
| Immunitybio, Inc. | 4 | $115 |
| Verity Pharmaceuticals Inc. | 5 | $111 |
| Myriad Genetic Laboratories, Inc. | 5 | $105 |
| KARL Storz Endoscopy-america | 4 | $104 |
| Bayer | 4 | $101 |
| Olympus America Inc. | 3 | $96 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $95 |
| Agiliti Surgical, Inc. | 2 | $92 |
| Urogen Pharma, Inc. | 3 | $81 |
| Myovant Sciences Inc. | 3 | $78 |
| Medtronic | 1 | $77 |
| Progenics Pharmaceuticals, Inc. | 3 | $66 |
| GE HealthCare | 1 | $56 |
| BD | 2 | $45 |
| Novartis | 2 | $45 |
| Photocure Inc | 2 | $43 |
| Endo Pharmaceuticals Inc. | 2 | $43 |
| Angiodynamics, Inc. | 1 | $35 |
| Teleflex LLC | 1 | $26 |
| Ambu Inc. | 1 | $24 |
| Coloplast | 1 | $22 |
| SRS Medical Systems, Inc. | 1 | $17 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
| Sagent Pharmaceuticals | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$286
- Dornier MedTech$205
- UroLift$138
- RYBREVANT$125
- CARVYKTI$125
How this compares
$11,567 in reported general payments places this provider in the 75th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 351 | $258,857 |
| ZytigaAbiraterone Acetate | 11 | $120,516 |
| GemtesaVibegron | 111 | $91,259 |
| Dutasteride | 702 | $25,163 |
| Tamsulosin Hcl | 1,341 | $23,597 |
| Finasteride | 714 | $8,660 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 328 | $7,246 |
| Testosterone | 35 | $5,971 |
| Potassium Citrate ErPotassium Citrate | 63 | $4,726 |
| Tolterodine Tartrate ErTolterodine Tartrate | 50 | $3,702 |
| Silodosin | 48 | $3,527 |
| Oxybutynin Chloride ErOxybutynin Chloride | 60 | $1,939 |
| Tadalafil | 42 | $1,515 |
| Solifenacin Succinate | 25 | $853 |
| Cephalexin | 127 | $737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,783 | $258,857351 claims |
| Johnson & JohnsonZytiga | $917 | $120,51611 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $2,470 | $91,259111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,324 urology providers in California.
Other urology in San Francisco
- Marc Dall'eraSan Francisco$1.4M
- Marshall StollerSan Francisco$898K
- Peter CarrollSan Francisco$786K
- Sima PortenSan Francisco$312K
- Edward UchioOrange$21.1M
- Stephen FreedlandWest Hollywood$16.7M
- Alec KooTorrance$7.4M
- Karim ChamieLos Angeles$4.3M
- Ralph ClaymanOrange$3.9M
- Siamak DaneshmandLos Angeles$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.